Acumen Pharmaceuticals, Inc. Operating Lease Cost
Acumen Pharmaceuticals, Inc. (ABOS) reported Operating Lease Cost of $37.00 thousand for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2024-08-13
- Acumen Pharmaceuticals, Inc. operating lease, cost for the quarter ending 2024-06-30 was $37.00K, a 7.50% decline year-over-year.
- Acumen Pharmaceuticals, Inc. operating lease, cost for the quarter ending 2024-03-31 was $37.00K, a 7.50% decline year-over-year.
- Acumen Pharmaceuticals, Inc. operating lease, cost for the quarter ending 2023-06-30 was $40.00K, a 5.26% increase year-over-year.
- Acumen Pharmaceuticals, Inc. operating lease, cost for the quarter ending 2023-03-31 was $40.00K, a 5.26% increase year-over-year.
- Acumen Pharmaceuticals, Inc. operating lease, cost for fiscal 2023 was $133.00K, a 13.64% decline from fiscal 2022.
- Acumen Pharmaceuticals, Inc. operating lease, cost for fiscal 2022 was $154.00K.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2024-06-30 | $37.00K 10-Q · filed 2024-08-13 | $74.00K 10-Q · filed 2024-08-13 | ||
| 2024-03-31 | $37.00K 10-Q · filed 2024-05-14 | |||
| 2023-12-31 | $133.00K 10-K · filed 2024-03-26 | |||
| 2023-06-30 | $40.00K 10-Q · filed 2024-08-13 | $80.00K 10-Q · filed 2024-08-13 | $120.00K derived: sum of 3 quarters · filed 2024-08-13 | $158.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $40.00K 10-Q · filed 2024-05-14 | $80.00K derived: sum of 2 quarters · filed 2024-05-14 | $118.00K derived: sum of 3 quarters · filed 2024-05-14 | $156.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $40.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $78.00K derived: sum of 2 quarters · filed 2024-03-26 | $116.00K derived: sum of 3 quarters · filed 2024-03-26 | $154.00K 10-K · filed 2024-03-26 |
| 2022-09-30 | $38.00K 10-Q · filed 2022-11-14 | $76.00K derived: sum of 2 quarters · filed 2022-11-14 | $114.00K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $38.00K 10-Q · filed 2022-08-15 | $76.00K 10-Q · filed 2022-08-15 | ||
| 2022-03-31 | $38.00K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |